Pathogenesis of Parkinson's disease: Oxidative stress, environmental impact factors and inflammatory processes

Neuroscience Bulletin

Volumn 23, Issue 2, 2007, Pages 125-130

  Yuan, Hong ^a,c   Zheng, Jing Chen ^a   Liu, Ping ^b   Zhang, Shao Feng ^a   Xu, Jian Yang ^a   Bai, Li Min ^c  

^a GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Environmental impact; Neurogenic inflammation; Oxidative stress; Parkinson's disease; Pathogenesis

Indexed keywords

CAFFEINE; CYTOKINE; FREE RADICAL; METAL; NITRIC OXIDE; PESTICIDE; REACTIVE SULFUR SPECIES;

APOPTOSIS; CIGARETTE SMOKING; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EXCITOTOXICITY; HEREDITY; HUMAN; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NERVE CELL DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; RISK FACTOR; SHORT SURVEY;

ANIMALS; ENVIRONMENTAL POLLUTANTS; HUMANS; INFLAMMATION; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 34249085348     PISSN: 16737067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12264-007-0018-x     Document Type: Short Survey

References (29)

1. Grunblatt E, Mandel S, Maor G, Youdim MB. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem 2001, 78: 1-12.
2. Di Monte DA. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2003, 2: 531-538.
3. Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med 2004, 10 suppl: S58-S62.
4. Schapira AH. Etiology of Parkinson's disease.Neurology 2006, 66 (10 Suppl 4): S10-S23.
5. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004, 3: 205-214.
6. Weber CA, Ernst ME. Antioxidants, supplements, and Parkinson's disease. Ann Pharmacother 2006, 40: 935-938.
7. Hald A, Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol, 2005, 193: 279-290
8. Lotharius, Brundin. Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat rev Neurosci 2002, 3: 932-942.
9. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003, 53 suppl 3: S26-S38.
10. Chen L, Thiruchelvam MJ, Madura K, Richfield EK. Proteasome dysfunction in aged human α-synuclein transgenic mice. Neurobiol Dis 2006, 23: 120-126.
11. Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect 2005, 113: 1250-1256.
12. Weiss B. Economic implications of manganese neurotoxicity. Neruotoxicology 2006, 27: 362-368.
13. Petrovitch H, Ross GW, Abbott RD, Sanderson WT, Sharp DS, Tanner CM, et al. Plantation work and risk of Parkinson's disease in a population-based longitudinal study. Arch Neurol 2002, 59: 1787-1792.
14. Ascherio A, Chen H, Weisskopf MG, O'Reilly E, McCullough ML, Calle EE, et al. Pesticide exposure and risk for Parkinson's disease. Ann Neurol 2006, 60: 197-203.
15. Brown TP, Rumsby PC, Capleton AC, Rushton L, Levy LS. Pesticides and Parkinson's disease - is there a link? Environ Health Perspect 2006, 114: 156-164.
16. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human á-synuclein. J Biol Chem 2001, 276: 44284-44296.
17. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997, 48: 650-658.
18. Jankovic J. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology 2005, 64: 2021-2028
19. Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001, 50: 56-63.
20. Tanner CM, Goldman SM, Aston DA, Ottman R, Ellenberg J, Mayeux R, et al. Smoking and Parkinson's disease in twins. Neurology 2002, 58: 581-588.
21. Arai H, Furuya T, Mizuno Y, Mochizuki H. Inflammation and infection in Parkinson's disease. Histol Histopathol 2006, 21: 673-678
22. Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm 2000, 60 (Suppl): 277-290.
23. Hakansson A, Westberg L, Nilsson S, Buervenich S, Carmine A, Holmberg B, et al. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2005, 133: 88-92.
24. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003, 53 suppl 3: S49-S60.
25. 2. Arch Biochem Biophys 2000, 374: 325-333.
26. Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci 1993, 13: 2651-2661.
27. Knott C, Stern G, Wilkin GP. Inflamatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenase-1 and -2. Mol Cell Neurosci 2000, 16: 724-739.
28. Hengartner MO. The biochemistry of apoptosis. Nature 2000, 407: 770-776.
29. Wersinger C, Sidhu A. An inflammatory pathomechanism for Parkinson's disease? Curr Med Chem. 2006, 13: 591-602.